CL2019000149A1 - Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652) - Google Patents

Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652)

Info

Publication number
CL2019000149A1
CL2019000149A1 CL2019000149A CL2019000149A CL2019000149A1 CL 2019000149 A1 CL2019000149 A1 CL 2019000149A1 CL 2019000149 A CL2019000149 A CL 2019000149A CL 2019000149 A CL2019000149 A CL 2019000149A CL 2019000149 A1 CL2019000149 A1 CL 2019000149A1
Authority
CL
Chile
Prior art keywords
tau
compositions
methods
useful
expression
Prior art date
Application number
CL2019000149A
Other languages
English (en)
Inventor
Ofengeim Manuela Polydoro
Jan Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019000149A1 publication Critical patent/CL2019000149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONAN EN ESTA SOLICITUD COMPOSICIONES Y MÉTODOS PARA DISMINUIR LA EXPRESIÓN DE PROTEÍNA Y ARNM TAU. ESTAS COMPOSICIONES Y MÉTODOS SON ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON TAU. PARTICULARMENTE, SE PROPORCIONAN EN LA PRESENTE SOLICITUD OLIGONUCLEÓTIDOS ANTISENTIDO QUE SE DIRIGEN A LA PROTEÍNA TAU ASOCIADA A MICROTÚBULO HUMANA (MAPT, CONFORME A SUS SIGLAS EN INGLÉS), COMPOSICIONES QUE COMPRENDEN LOS OLIGONUCLEÓTIDOS ANTISENTIDO, Y MÉTODOS PARA DISMINUIR LA EXPRESIÓN DE PROTEÍNA Y ARNM DE TAU USANDO ESTOS OLIGONUCLEÓTIDOS ANTISENTIDO. LAS COMPOSICIONES Y LOS MÉTODOS PROPORCIONADOS EN ESTE DOCUMENTO SON ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A TAU.
CL2019000149A 2015-12-21 2019-01-18 Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652) CL2019000149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562270165P 2015-12-21 2015-12-21

Publications (1)

Publication Number Publication Date
CL2019000149A1 true CL2019000149A1 (es) 2019-06-07

Family

ID=57758674

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018001652A CL2018001652A1 (es) 2015-12-21 2018-06-18 Composiciones y métodos para disminuir la expresión de tau
CL2019000149A CL2019000149A1 (es) 2015-12-21 2019-01-18 Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652)
CL2019003420A CL2019003420A1 (es) 2015-12-21 2019-11-25 Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociados a tau. (divisional solicitud 201801652)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018001652A CL2018001652A1 (es) 2015-12-21 2018-06-18 Composiciones y métodos para disminuir la expresión de tau

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003420A CL2019003420A1 (es) 2015-12-21 2019-11-25 Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociados a tau. (divisional solicitud 201801652)

Country Status (35)

Country Link
US (2) US11473083B2 (es)
EP (1) EP3394259B1 (es)
JP (3) JP7027328B2 (es)
KR (1) KR20180089517A (es)
CN (2) CN116218848A (es)
AR (1) AR107579A1 (es)
AU (2) AU2016376034B2 (es)
BR (1) BR112018012304A2 (es)
CA (1) CA3008094A1 (es)
CL (3) CL2018001652A1 (es)
CO (1) CO2018006297A2 (es)
CR (1) CR20200609A (es)
CU (1) CU24574B1 (es)
DK (1) DK3394259T3 (es)
DO (1) DOP2018000151A (es)
EA (2) EA202091865A1 (es)
EC (1) ECSP18050575A (es)
FI (1) FI3394259T3 (es)
HK (1) HK1254822A1 (es)
IL (3) IL296844B2 (es)
JO (2) JOP20200228A1 (es)
LT (1) LT3394259T (es)
MA (1) MA44426B1 (es)
MX (2) MX2018007726A (es)
MY (1) MY191737A (es)
PE (1) PE20181448A1 (es)
PH (1) PH12018501207A1 (es)
PT (1) PT3394259T (es)
RU (1) RU2747734C2 (es)
SA (1) SA518391831B1 (es)
SG (2) SG11201804704PA (es)
SV (1) SV2018005714A (es)
TW (2) TWI787163B (es)
UY (1) UY37038A (es)
WO (1) WO2017109679A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6492003B2 (ja) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
JP2021515784A (ja) * 2018-03-13 2021-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法
JP7102557B2 (ja) 2018-07-03 2022-07-19 エフ．ホフマン－ラ ロシュ アーゲー Ｔａｕ発現調節用オリゴヌクレオチド
US20230203486A1 (en) * 2020-03-30 2023-06-29 Alnylam Pharmaceuticals, Inc. MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
CA3221625A1 (en) * 2021-06-16 2022-12-22 Omri GOTTESMAN Treatment of mtres1 related diseases and disorders
WO2024091874A1 (en) * 2022-10-25 2024-05-02 Empirico Inc. Gene therapy treatment of mtres1 related diseases and disorders

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
WO1991010671A1 (en) 1990-01-11 1991-07-25 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US20020052331A1 (en) 1990-08-14 2002-05-02 Brenda Baker Compositions and methods for antisense inhibition of protein translation
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
DE69233767D1 (de) 1991-12-06 2009-09-17 Max Planck Gesellschaft Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
CA2162361C (en) 1993-05-11 2008-10-21 Ryszard Kole Antisense oligonucleotides which combat aberrant splicing and methods of using the same
DE69729179T2 (de) 1996-02-14 2004-12-30 Isis Pharmaceuticals, Inc., Carlsbad Lückenhaft Zucker-modifizierte Oligonukleotide
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
JP2002513551A (ja) 1998-05-01 2002-05-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 病原性タウ突然変異
AU762812B2 (en) * 1998-07-14 2003-07-03 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6350868B1 (en) 1999-04-26 2002-02-26 University Of North Carolina At Chapel Hill Antisense human fucosyltransferase sequences and methods of use thereof
CN101284873A (zh) * 1999-06-30 2008-10-15 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
AU2001229619A1 (en) 2000-01-21 2001-07-31 Pharmacia And Upjohn Company Transgenic mouse model of human neurodegenerative disease
CA2400595A1 (en) * 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
WO2002055681A2 (en) 2001-01-11 2002-07-18 Bayer Ag Regulation of human tau-tubulin kinase
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
WO2004003134A2 (en) 2002-06-26 2004-01-08 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7906326B2 (en) 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
KR20110007263A (ko) 2003-08-28 2011-01-21 노파르티스 아게 블런트-말단 및 3＇-변형체를 갖는 간섭 ｒｎａ 이중나선
WO2005040382A2 (de) 2003-10-28 2005-05-06 Alexander Cherkasky Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
EP3228711A1 (en) 2004-06-28 2017-10-11 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US7312035B2 (en) 2004-09-03 2007-12-25 Affymetrix, Inc. Methods of genetic analysis of yeast
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
CA2587601C (en) 2004-12-03 2017-11-07 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
EP1937312B1 (en) 2005-08-30 2016-06-29 Ionis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
WO2007047913A2 (en) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
GB0605337D0 (en) * 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
WO2008002620A2 (en) 2006-06-27 2008-01-03 University Of Virginia Patent Foundation Cell model for alzheimer's disease pathology
JP2010509923A (ja) 2006-11-23 2010-04-02 ミルクス セラピューティクス アンパーツゼルスカブ 標的ｒｎａの活性を変化させるためのオリゴヌクレオチド
EP2578692B1 (en) 2007-04-05 2016-06-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
JP5963678B2 (ja) 2009-11-12 2016-08-03 ジ ユニバーシティ オブ ウェスタン オーストラリア 病状を治療するためのアンチセンス分子及び方法
US20150018223A1 (en) 2010-01-28 2015-01-15 University Of Massachusetts Lowell Methods of diagnosing tau-associated neurodegenerative diseases
WO2011117353A1 (en) 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
US9145557B2 (en) 2010-11-23 2015-09-29 Mirrx Therapeutics A/S Oligonucleotides for modulation of target RNA activity
CA2822462A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
US9957558B2 (en) * 2011-04-28 2018-05-01 Life Technologies Corporation Methods and compositions for multiplex PCR
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
JP6492003B2 (ja) * 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
WO2014064187A1 (en) 2012-10-24 2014-05-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A microtubuli-modifying compound
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
JP2016502858A (ja) 2012-12-20 2016-02-01 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物
US20160040162A1 (en) 2013-03-14 2016-02-11 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
JP6449231B2 (ja) 2013-03-14 2019-01-09 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
CN111254145A (zh) 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
WO2014201306A1 (en) 2013-06-12 2014-12-18 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
TW202246503A (zh) * 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015068075A2 (en) 2013-10-24 2015-05-14 Institut National De La Sante Et De La Recherche Medicale Detection of tau
WO2016011123A1 (en) * 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
WO2016019063A1 (en) 2014-07-29 2016-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
EP3653712B1 (en) 2015-02-04 2022-11-30 F. Hoffmann-La Roche AG Tau antisense oligomers and uses thereof
CN107636159B (zh) 2015-02-04 2022-06-14 百时美施贵宝公司 选择治疗性分子的方法
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases

Also Published As

Publication number Publication date
RU2018126545A3 (es) 2020-10-12
RU2747734C2 (ru) 2021-05-13
AU2020267282A1 (en) 2020-12-10
EP3394259A1 (en) 2018-10-31
EA201891468A1 (ru) 2018-12-28
AU2020267282B2 (en) 2023-05-18
JP2021118732A (ja) 2021-08-12
MA44426B1 (fr) 2024-05-31
CL2018001652A1 (es) 2018-08-10
ECSP18050575A (es) 2018-07-31
WO2017109679A1 (en) 2017-06-29
JP2022065096A (ja) 2022-04-26
PE20181448A1 (es) 2018-09-12
IL296844B1 (en) 2023-12-01
RU2021112980A (ru) 2021-05-28
AU2016376034A1 (en) 2018-07-05
CA3008094A1 (en) 2017-06-29
SA518391831B1 (ar) 2022-08-16
IL260124A (en) 2018-07-31
TWI787163B (zh) 2022-12-21
CU20180065A7 (es) 2018-11-06
CU24574B1 (es) 2022-01-13
IL296844A (en) 2022-11-01
JO3790B1 (ar) 2021-01-31
TW201733597A (zh) 2017-10-01
MY191737A (en) 2022-07-13
PH12018501207A1 (en) 2019-02-11
CN116218848A (zh) 2023-06-06
EP3394259B1 (en) 2024-02-28
SG10201913434PA (en) 2020-03-30
TWI834177B (zh) 2024-03-01
US11473083B2 (en) 2022-10-18
JOP20200228A1 (ar) 2017-06-16
IL296844B2 (en) 2024-04-01
SG11201804704PA (en) 2018-07-30
AU2016376034B2 (en) 2020-12-03
KR20180089517A (ko) 2018-08-08
PT3394259T (pt) 2024-05-20
CN109072237A (zh) 2018-12-21
BR112018012304A2 (pt) 2019-02-05
CR20200609A (es) 2021-02-17
CO2018006297A2 (es) 2018-07-10
MX2018007726A (es) 2018-08-15
CN109072237B (zh) 2022-12-16
MX2023008211A (es) 2023-07-18
RU2021112980A3 (es) 2021-12-28
DK3394259T3 (da) 2024-05-27
JP7027328B2 (ja) 2022-03-01
DOP2018000151A (es) 2018-09-15
SV2018005714A (es) 2018-09-10
TW202311530A (zh) 2023-03-16
JP2019500428A (ja) 2019-01-10
UY37038A (es) 2017-07-31
RU2018126545A (ru) 2020-01-23
IL305866A (en) 2023-11-01
US20220411796A1 (en) 2022-12-29
CL2019003420A1 (es) 2020-05-15
FI3394259T3 (fi) 2024-05-24
AR107579A1 (es) 2018-05-16
EA036417B1 (ru) 2020-11-09
HK1254822A1 (zh) 2019-07-26
LT3394259T (lt) 2024-06-10
EA202091865A1 (ru) 2021-01-29
US20170175116A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
CL2019000149A1 (es) Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652)
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017011484A2 (es) Inhibidores de bromodominio
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
BR112017008696A2 (pt) métodos e composições para células exterminadoras naturais
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
GT201700188A (es) Anticuerpos contra tau y sus usos
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
BR112017009599A2 (pt) composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal
AR106320A1 (es) Moléculas de ácido nucleico que codifican la proteína troponina i (gen wupa) que confieren resistencia a plagas de coleópteros y hemípteros
CL2018000336A1 (es) Composición para el tratamiento de la mucosidad en las branquias de los peces
UY36421A (es) Compuestos para tratar el cáncer
UY36436A (es) Supresión del arni parental de genes de remodelación de cromatina para controlar plagas de coleópteros
UY35730A (es) Composiciones farmacéuticas comprendiendo kisspeptin o sus derivados